# Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

> **NCT05538195** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer
- Colon Cancer
- Rectal Cancer
- Esophageal Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** CEA-targeted CAR-T cells
- **BIOLOGICAL:** CEA-targeted CAR-T cells

## Key facts

- **NCT ID:** NCT05538195
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-07
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-06-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05538195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05538195, "Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05538195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*